XENE Stock Summary and Trading Ideas (Xenon Pharmaceuticals - Common Shares | NASDAQ:XENE)

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals - Common Shares trades on the NASDAQ stock market under the symbol XENE.

As of June 22, 2026, XENE stock price climbed to $54.79 with 1,774,168 million shares trading.

XENE has a beta of 0.50, meaning it tends to be less sensitive to market movements. XENE has a correlation of 0.02 to the broad based SPY ETF.

XENE has a market cap of $5.30 billion. This is considered a Mid Cap stock.

Last quarter Xenon Pharmaceuticals - Common Shares reported $0 in Revenue and -$1.17 earnings per share. This fell short of revenue expectation by $-4 million and exceeded earnings estimates by $.02.

In the last 3 years, XENE traded as high as $63.95 and as low as $26.74.

The top ETF exchange traded funds that XENE belongs to (by Net Assets): IWM, IWO, IBB, VTWO, SPDW.

XENE has outperformed the market in the last year with a price return of +71.8% while the SPY ETF gained +26.5%. However, in the short term, XENE had mixed performance relative to the market. It has underperformed in the last 3 months, returning -0.5% vs +13.1% return in SPY. But in the last 2 weeks, XENE shares have fared better than the market returning +3.4% compared to SPY -1.4%.

XENE support price is $51.89 and resistance is $53.93 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that XENE shares will trade within this expected range on the day.